06:37 AM EDT, 08/20/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Tuesday that China's health regulator has approved its drug, Fasenra, as a maintenance treatment for severe eosinophilic asthma in patients aged 12 and older.

The health agency's decision was based on a late-stage trial that showed that Fasenra significantly reduced the annualized asthma exacerbation rate by 74% when added to the standard of care compared to placebo.

Fasenra is already approved in over 80 countries, including the US, Japan, and the EU.

Price: 85.41, Change: +0.63, Percent Change: +0.74